MangoRx's new $99/mo injectable TRT sees 336% MoM sales growth, 54% CAC drop

MANGOCEUTICALS, INC.

Month-over-month sales of injectable TRT program increased 336% since mid-December 2025 launch.
Customer acquisition cost reduced by 54% over the same period.
Global TRT market valued at $2.11-2.2B in 2025, expected CAGR 3.9% (TBRC report).
CEO Jacob Cohen: TRT is key strategic focus; platform evolving to broader men's health.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.